This site is intended for Healthcare professionals only.

Cipla launches respiratory inhalation therapy product Niveoli in India

Cipla launches respiratory inhalation therapy product Niveoli in India

New Delhi: Drug major Cipla Friday announced the launch of its proprietary respiratory inhalation therapy product ‘Niveoli’ in India. Niveoli is used in respiratory inhalation therapy that addresses an unmet need associated with obstructive airway diseases (OAD) such as asthma and chronic obstructive pulmonary disorder (COPD), Cipla said in a BSE filing.

Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow.The main symptoms include shortness of breath and cough with sputum production

Also Read: Cipla to launch Cinacalcet Hydrochloride tablets, a generic version of Sensipar

The company said Niveoli, extra-fine particle beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler for adults, targets drug delivery to the small airways.

“We see our market leadership, as well as the range and depth of our R&D and manufacturing capabilities in this therapy as a privilege and a responsibility to do more for patients,” Cipla Head – India business Nikhil Chopra said.

Cipla Limited is a multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India. The company primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions.

The following two tabs change content below.
Farhat Nasim

Farhat Nasim

Farhat Nasim joined Medical Dialogue as Reporter in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier's College Ranchi. She can be contacted at Contact no. 011-43720751

Source: With input
0 comment(s) on Cipla launches respiratory inhalation therapy product Niveoli in India

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted